Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 537 results for syndrome

  1. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  2. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

  3. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  4. External aortic root support in Marfan syndrome (IPG394)

    This guidance has been updated and replaced by NICE HealthTech guidance 623.

  5. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

  6. Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158)

    This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.

  7. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  8. What is the most clinically and cost-effective dual antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention (PCI)?

    antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention...

  9. Open femoro–acetabular surgery for hip impingement syndrome (IPG403)

    Interventional procedures, IPG403 - Issued: July 2011 --> We have moved interventional procedures guidance 403 to become HealthTech guidance 270. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. Arthroscopic femoro–acetabular surgery for hip impingement syndrome (IPG408)

    Interventional procedures, IPG408 - Issued: September 2011 --> We have moved interventional procedures guidance 408 to become HealthTech guidance 273. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

  12. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe...

  13. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

  14. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .